Wulf Fischer-Knuppertz Appointed New CEO of BIOCRATES Life Sciences AG
INNSBRUCK, Austria, June 18, 2013 /PRNewswire/ –
On 1 June 2013, Dr Wulf Fischer-Knuppertz, took over as Chief Executive Officer (CEO)
of the internationally operating biotech company BIOCRATES Life Sciences AG. He will from
now on be responsible for the company’s corporate and strategic management.
For more than 25 years, Dr Fischer-Knuppertz has held various leading positions in the
diagnostics and pharmaceutical industries. Most recently, 56-year-old Fischer-Knuppertz,
who holds a PhD in veterinary medicine, was General Manager with Fisher Scientific and
before that had held leading positions at Roche Diagnostics. In the field of diagnostics,
Fischer-Knuppertz brings not only ample experience in General Management, Business
Development, and Marketing and Sales but also an in-depth know-how in personalized
medicine to the job.
Fischer-Knuppertz enthusiastically commented his appointment: “I am very attracted to
BIOCRATES` unique targeted metabolomics platform capabilities. The technology is highly
innovative and has a huge commercial potential. I look forward to establishing
relationships and innovative collaborations that will showcase this exceptional
metabolomics platform and contribute to BIOCRATES` growth and continued success.”
The technical and scientific responsibilities within the BIOCRATES Life Sciences AG
management team will continue to be fulfilled by Chief Technology Officer Dr Ralph Zahn.
The former Chairman of the Board, Elgar Schnegg, will be leaving the company in an
atmosphere of excellent mutual understanding on 30 June 2013.
BIOCRATES Life Sciences AG is a leading biotechnology company based in
Innsbruck/Austria focused on the development of metabolomics products and in vitro
diagnostics (IVDs) for early disease and progression detection in areas such as
nephrology, diabetes, oncology, and endocrinology. The company’s mass-spectrometry-based,
standardized metabolomic kits and IVDs provide unprecedented accuracy, precision, and
multiplexing potential that will help revolutionize the way personalized medicine is
applied in R&D and diagnostics.
For more information, please go to http://www.biocrates.com.
For further inquiries, please contact: BIOCRATES Life Sciences AG Martina Klocker Martina.Klocker@biocrates.com Phone +43-(0)512-579823
SOURCE BIOCRATES Life Sciences AG